ГІПЕРАКТИВАЦІЯ СИМПАТИЧНОЇ НЕРВОВОЇ СИСТЕМИ У ХВОРИХ НА ХРОНІЧНУ ХВОРОБУ НИРОК: ВІД ПАТОГЕНЕЗУ ДО ЛІКУВАННЯ
Анотація
Симпатична нервова система відіграє важливу роль у розвитку серцево-судинних ускладнень у хворих на хронічну хворобу нирок (ХХН). Метою даного огляду є узагальнення наявних знань про роль симпатичної гіперактивації у патогенезі ХХН, її клінічне значення та можливості сучасного лікування.
Завантаження
Посилання
Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis / Kavi J. Littlewood, Wolfgang Greiner, Dominique Baum, [et al.] // [Електронний ресурс]: BMC Nephrol. – 2007. – V. 8. – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976090/.
All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan / C. P.Wen, T. Y. D. Cheng, M. K. Tsai [et al.] // The Lancet. – 2008. – V. 371. – № 9631. – P. 2173–2182.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis / Mahmoodi B. K., Matsushita K., Woodward M., [et al.] // Lancet. – 2012. – V. 380. – P. 1649-1661.
Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. / K. Masuo, H. Rakugi, T. Ogihara, M. D. Esler, G. W. Lambert // Current Diabetes Reviews. – 2010. – V. 6. – № 2. – P. 58-67.
Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors / Shlipak M. G., Fried L. F., Cushman M., [et al.] // JAMA. – 2005. – V. 293. – P. 1737-1745.
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women / M. K. Pöyhönen-Alho, K. Manhem, [et al.] // Journal of Hypertension. – 2008. – V. 26. – №12. – Р. 2445-2449.
Chazova I. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study / Irina Chazova, Markus P. Schlaich // [Електронний ресурс]: International Journal of Hypertension. – 2013. – V. 2013. – Режим доступу: http://www.hindawi.com/journals/ijht/2013/541689/
Desir G. V. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease / Desir G. V. // Curr. Opin. Nephrol. Hypertens. – 2008. – V. 17. – Р. 181-185.
Device-Based Antihypertensive Therapy. Therapeutic Modulation of the Autonomic Nervous System / H. Krum, P. Sobotka, M. Bo¨hm, M. Esler, [et al.] // Circulation. – 2011. – V. 123. – Р. 209-215.
Early sympathetic activation in the initial clinical stages of chronic renal failure / Grassi G., Quarti-Trevano F., Seravalle G., [et al.] // Hypertension. – 2011. – V. 57. – P. 846-851.
Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats / K. Amann, L. Christian Rump, A. Simonaviciene, [et al.] // JASN. – 2000. – V. 11. – № 8. – Р. 1469- 1478.
Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease / Hausberg M., Tokmak F., Pavenstädt H., [et al.] // J. Hypertens. – 2010. – V. 28(9). – P. 1920-1927.
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? / P. Stenvinkel, J. J. Carrero, [et al.] // Clinical Journal of the American Society of Nephrology. – 2008. – V. 3. – № 2. – Р. 505-521.
ESH position paper: renal denervation - an interventional therapy of resistant hypertension / Schmieder R. E., Redon J., Grassi G., Kjeldsen S. E., [et al.] // J Hypertens. – 2012. – V. 30(5). – Р. 837-841.
Eva E. Vink. Sympathetic Hyperactivity in Chronic Kidney Disease: Pathophysiology and (New) Treatment Options / Eva E. Vink, Rosa L. de Jager, Peter J. Blankestijn // Current Hypertension Reports. – 2013. – V. 15. – № 2. – Р. 95-101.
Fisher J. P. Central sympathetic overactivity: maladies and mechanisms / J. P. Fisher, C. N. Young, and P. J. Fadel // Autonomic Neuroscience. – 2009. – V. 148. – № 1-2. – Р. 5-15.
Jeanie Park. Cardiovascular Risk in Chronic Kidney Disease: Role of the Sympathetic Nervous System / Jeanie Park // [Електронний ресурс] : Cardiology Research and Practice. – V. 2012. – Режим доступу: http://www.hindawi.com/journals/crp/2012/319432/
Joyner M. J. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications / Joyner M. J., Charkoudian N., Wallin B. G. // Hypertension. – 2010. – V. 56. – Р. 10-6.
Low glomerular filtration rate and risk of stroke: meta-analysis / Lee M., Saver J. L., Chang K. H., Liao H. W., [et al.] // [Електронний ресурс] : BMJ. – 2010. – V. 30 – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948650/
Major pathways of the reno–cardiovascular link: the sympathetic and renin– angiotensin systems / P. J. Blankestijn, G. London, D. Fliser, K. J. Jager, [et al.] // Kidney International Supplements. – 2011. – V. 1(1). – Р. 13-16.
Markus P. Schlaich. Sympathetic Activation in Chronic Kidney Disease : Out of the Shadow / Markus P. Schlaich // Hypertension. – 2011. – V. 57. – P. 683- 685.
Matsushita K. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis / K. Matsushita, M. van der Velde, B. C. Astor, [et al.] // The Lancet. – 2010. – V. 375. – № 9731. – Р. 2073-2081.
Mechanisms of autonomic nervous system dysfunction in uremia / Campese V. M., Romoff M. S., Levitan D., [et al.] // Kidney Int. – 1981. – V. 20. – Р. 246- 253.
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial / G. Derosa, A. F. G. Cicero, A. D'Angelo [et al.] // Clinical Therapeutics. – 2007 – V. 29. – № 4. – Р. 602– 610.
Minushkina L. O. Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes / Minushkina L. O. // Kardiologiia. – 2011. – V. 51(4). – Р. 74-78.
Modulation of peripheral chemoreflex by neurohumoral adaptations after kidney transplantation / Rassaf T., Westenfeld R., Balzer J., [et al.] // Eur. J. Med. – 2010. – 15. – Suppl. 2. – Р. 83-87.
Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt / H. Aceros, G. Farah, L. Cobos- Puc, [et al.] // Br. J. Pharmacol. – 2011. – V. 164(3). – Р. 946-957.
Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan- treated chronic renal failure / Neumann J., Ligtenberg G., Oey L., [et al.] // J. Am. Soc. Nephrol. – 2004. – V. 11. – Р. 2902-2907.
Moxonidine prevents ischemia/reperfusion-induced renal injury in rats / Tsutsui H., Sugiura T., Hayashi K., [et al.] // Eur. J. Pharmacol. – 2009. – V. 28; 603(1-3). – P. 73-78.
Murray Esler. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management / Murray Esler // Journal of Applied Physiology – 2010. – V. 108. – № 2. – Р. 227-237.
Murray Esler. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension / Murray Esler // Experimental Physiology – 2011 – V. 96. – Р. 611-622.
Parati G. The human sympathetic nervous system: its relevance in hypertension and heart failure / Gianfranco Parati, Murray Esler // European Heart Journal. – 2012. – V. 33. – Р. 1058-1066.
Peter J. Blankestijn. Sympathetic hyperactivity in chronic kidney disease / Peter J. Blankestijn // Nephrol. Dial. Transplant. – 2004 – V. 19. – Р. 1354- 1357.
Pharmacological properties of the central antihypertensive agent, moxonidine / Edwards L. P., Brown-Bryan T. A., McLean L., Ernsberger P. // Cardiovasc Ther. – 2012. – V. 30(4). – P. 199-208.
Plasma levels of norepinephrine and dopamine-β-hydroxylase in CRF patients treated with dialysis / Lake C. R., Ziegler M. G., Coleman M. D., Kopin I.J. // Cardiovasc. Med. – 1979. – V. 4. – Р. 1099-1111.
Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research / Ott C., Schmid A., Ditting T., Sobotka P. A. // J. Clin. Hypertens. – 2012. – V. 14(11). – P. 799-801.
Renal Denervation Ultima Ratio or Standard in Treatment-Resistant Hypertension / A. Persu, J. Renkin, L. Thijs, . J. A. Staessen // Hypertension. – 2012. – V. 60(3). – Р. 596-606.
Renalase's Expression and Distribution in Renal Tissue and Cells / F. Wang, T. Xing, J. Li, [et al.] // [Електронний ресурс] : PLoS One. – 2012. – V. 7(10) – Режим доступу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463591/#pone.0046442-Xu1
Ritz E. Control of sympathetic activity – new insights; new therapeutic targets? / Ritz E., Rump L. C. // Nephrol. Dial. Transplant. – 2010. – №: 10. – Р. 1048- 1050.
Rucker D. Cardiovascular risk and management in chronic kidney disease / D. Rucker, M. Tonelli // Nature Reviews Nephrology. – 2009. – V. 5. – № 5. – Р. 287-296.
Simon C. Malpas. Sympathetic Nervous System Overactivity and Its Role in the Development of Cardiovascular Disease / Simon C. Malpas // Physiol Rev. – 2010. – V. 9. – №. 2. – Р. 513-557.
Sudden cardiac death in hemodialysis patients: an in-depth review / D. Green, P. R. Roberts, D. I. New, and P. A. Kalra // American Journal of Kidney Diseases. – 2011. – V. 57. – № 6. – Р. 921-929.
Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment / Laima Siddiqi, Niek H. Prakken, Birgitta K. Velthuis, [et al.] // Nephrol. Dial. Transplant. – 2010. – V. – 2. (10). – P. 3272-3277.
Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension / Klein I. H., Ligtenberg G., Oey P. L., [et al.] // J. Am. Soc Nephrol. – 2001– № 24. – Р. 27-2433.
Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment / Penne E. L., Neumann J., Klein I. H., [et al.] J. Nephrol. – 2009. – V. 22. – P. 208-215.
Sympathetic nervous activation in obesity and the metabolic syndrome – causes, consequences and therapeutic implications / G. W. Lambert, N. E. Straznicky, E. A. Lambert, J. B. Dixon, M. P. Schlaich // Pharmacology and Therapeutics. – 2010. – V. 126, – № 2. – P. 159-172.
Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults / E. Lambert, C. I. Sari, T. Dawood, [et al.] // Hypertension. – 2010. – V. 56. – № 3. – P. 351-358.
Sympathetic overactivity in patients with chronic renal failure / Converse R. L., Jacobsen T. N., Toto R. D., Jost C. M., [et al.] // N. Engl. J. Med. – 1992. – V. 327. – P. 1912-1918.
Sympatho-renal axis in chronic disease / Paul A. Sobotka, Felix Mahfoud, Markus P. Schlaich, [et al] // Clin Res Cardiol. – 2011. – V. 100. – P. 1049- 1057.
The role of sympathetic nervous activity in renal injury and end-stage renal disease / Masuo K., Lambert G. W., Esler M. D., Rakugi H. // Hypertens Res. – 2010. – V. 33(6). – P. 521-528.
Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? / Ditting T., Freisinger W., Siegel K., [et al.] // Hypertension. – 2012. – V. 59. – P. 467-476.
Volders P. G. A. Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis / Volders P. G. A. // Heart Rhythm. – 2010. – V. 71. – № 2. – Р. 1900-1906.
Yaduvanshi A. CRT-128 Renal Artery Denervation in Chronic Kidney Disease Patients / A. Yaduvanshi, M. Nair // J. Am. Coll. Cardiol. Intv. – 2013. – V. 6 (2_S). – Р. S41-S42.
Журнал розповсюджується за ліцензією 